Karl C. Mayer, Facharzt für Neurologie, Psychiatrie und Facharzt für Psychotherapeutische Medizin, Psychoanalyse

          Suche  Inhaltsverzeichnis  Glossar: A B C D E F G H I J K L M N O P Q R S T U V W X Y


Literaturliste Demenz

        home-brt.gif (1287 Byte)


Literatur zum Kapitel Demenz (teilweise nur direkt im Kapitel als Link ausgewiesen). Je nach Zeitschrift sind nicht alle Artikel im Volltext frei abrufbar. Zeitschriften wie das BMJ haben alle Artikel frei, manche Zeitschriften erwarten eine Registrierung und haben auch dann nur ältere Artikel frei verfügbar. Für Abonnenten sind nach Registrierung bei allen Zeitschriften die Artikel frei verfügbar.

Zurück zur Startseite Demenz


    1. Mahyar Etminan, Sudeep Gill, and Ali Samii, Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ 2003; 327: 128.[Abstract] [Abridged text] [Abridged PDF] [Full text] [PDF]
    2. A. D. Smith Imaging the progression of Alzheimer pathology through the brain PNAS, April 2, 2002; 99(7): 4135 - 4137. [Full Text] [PDF]
    3. A. P. Porsteinsson, P. N. Tariot, R. Erb, C. Cox, E. Smith, L. Jakimovich, J. Noviasky, N. Kowalski, C. J. Holt, and C. Irvine Placebo-Controlled Study of Divalproex Sodium for Agitation in Dementia Am. J. Geriatr. Psychiatry, February 1, 2001; 9(1): 58 - 66.  [Abstract] [Full Text]
    4. A. Stevens, R. Milne, R. Lilford, and J. Gabbay Keeping pace with new technologies: systems needed to identify and evaluate them BMJ, November 13, 1999; 319(7220): 1291 - 1291. [Full Text] 
    5. Abdel-sayed WS, Toppozada HK, Said SA, El-sayed OK. Some metabolic and hormonal changes in women using long acting injectable contraceptives. Alex J Pharm Sci. 1989;3:29-32. MEDLINE
    6. Abraham, W. C., Logan, B., Greenwood, J. M., Dragunow, M. (2002). Induction and Experience-Dependent Consolidation of Stable Long-Term Potentiation Lasting Months in the Hippocampus. J. Neurosci. 22: 9626-9634 [Abstract] [Full Text]
    7. Ahmed, S., Mozley, P. D., Potter, W. Z. (2002). Biomarkers in Psychotropic Drug Development. AJGP 10: 678-686 [Abstract] [Full Text]  
    8. Aisen, P. S., Egelko, S., Andrews, H., Diaz-Arrastia, R., Weiner, M., DeCarli, C., Jagust, W., Miller, J. W., Green, R., Bell, K., Sano, M. (2003). A Pilot Study of Vitamins to Lower Plasma Homocysteine Levels in Alzheimer Disease. AJGP 11: 246-249 [Abstract] [Full Text]  
    9. Andrieu et al. Association of Alzheimer's Disease Onset With Ginkgo Biloba and Other Symptomatic Cognitive Treatments in a Population of Women Aged 75 Years and Older From the EPIDOS Study J Gerontol A Biol Sci Med Sci 2003;58:M372-377. ABSTRACT | FULL TEXT  
    10. Ang-Lee et al. Herbal Medicines and Perioperative Care JAMA 2001;286:208-216. ABSTRACT | FULL TEXT  
    11. Astin Complementary and Alternative Medicine and the Need for Evidence-based Criticism Acad Med 2002;77:864-868. FULL TEXT  
    12. B. LAWLOR Managing behavioural and psychological symptoms in dementia Br. J. Psychiatry, December 1, 2002; 181(6): 463 - 465.  [Full Text] [PDF]  
    13. B. Pitt Coping with loss: Loss in late life BMJ, May 9, 1998; 316(7142): 1452 - 1454. [Full Text]
    14. Bartels et al. Evidence-Based Practices in Geriatric Mental Health Care PS 2002;53:1419-1431. ABSTRACT | FULL TEXT  
    15. Bartels, S. J., Dums, A. R., Oxman, T. E., Schneider, L. S., Arean, P. A., Alexopoulos, G. S., Jeste, D. V. (2002). Evidence-Based Practices in Geriatric Mental Health Care. PS 53: 1419-1431 [Abstract] [Full Text]  
    16. Bernabei Review: Ginkgo biloba extract improves cognitive function in mild to moderate Alzheimer's disease Evid Based Ment Health 1999;2:82-82. FULL TEXT  
    17. Biegon, A., Alvarado, M., Budinger, T. F., Grossman, R., Hensley, K., West, M. S., Kotake, Y., Ono, M., Floyd, R. A. (2002). Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J Neurochem 82: 924-934 [Abstract] [Full Text]  
    18. Birkenhäger WH, Forette F, Seux ML, Wang JG, Staessen JA. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension.Arch Intern Med.2001;161:152-156.
      Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.Neurobiol Aging.2000;21:153-160.
    19. Borroni, B., Agosti, C., Panzali, A.F., Di Luca, M., Padovani, A., Miller, J.W., Green, R., Mungas, D.M., Reed, B.R., Jagust, W.J. (2002). Homocysteine, vitamin B6, and vascular disease in patients with AD. Neurology 59: 1475-1476 [Full Text]  
    20. Boutaud, O., Ou, J. J., Chaurand, P., Caprioli, R. M., Montine, T. J., Oates, J. A. (2002). Prostaglandin H2 (PGH2 ) accelerates formation of amyloid {beta}1-42 oligomers. J Neurochem 82: 1003-1006 [Abstract] [Full Text]  
    21. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol. 2000;12:351-354. MEDLINE
    22. Bowen RL, Smith MA, Harris PL, et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 2002;70:514-518. MEDLINE
    23. Braak, H. & Braak, E. (1991) Acta Neuropathologica 82, 239-259
    24. Breitner, J. C.S., Zandi, P. P. (2001). Do Nonsteroidal Antiinflammatory Drugs Reduce the Risk of Alzheimer's Disease?. N Engl J Med 345: 1567-1568 [Full Text]  
    25.  Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140:262-267. MEDLINE 
    26. Buccafusco and Terry Multiple Central Nervous System Targets for Eliciting Beneficial Effects on Memory and Cognition J. Pharmacol. Exp. Ther. 2000;295:438-446. ABSTRACT | FULL TEXT  
    27. Burggren, A. C., Small, G. W., Sabb, F. W., Bookheimer, S. Y. (2002). Specificity of Brain Activation Patterns in People at Genetic Risk for Alzheimer Disease. AJGP 10: 44-51 [Abstract] [Full Text]  
    28. Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., Mucke, L. (2002). Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid beta Peptides But Not on Plaque Formation. J. Neurosci. 22: 10539-10548 [Abstract] [Full Text]  
    29.  C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. Menopause. 2000;7:273-281. MEDLINE
    30. C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study JAMA, September 25, 2002; 288(12): 1475 - 1483.  [Abstract] [Full Text] [PDF]  
    31. Calabrese Psycho 28/2002
    32. Chang, L., Speck, O., Miller, E. N., Braun, J., Jovicich, J., Koch, C., Itti, L., Ernst, T. (2001). Neural correlates of attention and working memory deficits in HIV patients. Neurology 57: 1001-1007 [Abstract] [Full Text]  
    33. Christen Oxidative stress and Alzheimer disease1 Am. J. Clin. Nutr. 2000;71:621s-629.ABSTRACT | FULL TEXT  
    34. D. Melzer Personal paper: New drug treatment for Alzheimer's disease: lessons for healthcare policy BMJ, March 7, 1998; 316(7133): 762 - 764. [Full Text]
    35. Day, M., Morris, R. G. M., Shimizu, E., Tang, Y.-P., Rampon, C., Feng, R., Shrom, D., Tsien, J. Z. (2001). Memory Consolidation and NMDA Receptors: Discrepancy Between Genetic and Pharmacological Approaches. Science 293: 755a-755 [Full Text]
    36. De Bree, A., Verschuren, W. M. M., Kromhout, D., Kluijtmans, L. A. J., Blom, H. J. (2002). Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease. Pharmacological Reviews 54: 599-618 [Abstract] [Full Text]  
    37. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA, Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb;60(2):107-15
    38. DE LA TORRE, J. C. (2002). Vascular Basis of Alzheimer's Pathogenesis. Annals NYAS Online 977: 196-215 [Abstract] [Full Text]  
    39. den Heijer, T., Vermeer, S. E, Clarke, R., Oudkerk, M., Koudstaal, P. J., Hofman, A., Breteler, M. M. B. (2002). Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126: 170-175 [Abstract] [Full Text]  
    40. Di Ciano, P., Cardinal, R. N., Cowell, R. A., Little, S. J., Everitt, B. J. (2001). Differential Involvement of NMDA, AMPA/Kainate, and Dopamine Receptors in the Nucleus Accumbens Core in the Acquisition and Performance of Pavlovian Approach Behavior. J. Neurosci. 21: 9471-9477 [Abstract] [Full Text]
    41. Dik, M. G., Jonker, C., Comijs, H. C., Bouter, L. M., Twisk, J. W.R., van Kamp, G. J., Deeg, D. J.H. (2001). Memory complaints and APOE-{epsilon}4 accelerate cognitive decline in cognitively normal elderly. Neurology 57: 2217-2222 [Abstract] [Full Text]  
    42. Elevated Homocysteine Is a Risk Factor for Alzheimer's Disease. Journal Watch Neurology 2002: 4-4 [Full Text]  
    43. Eric M. Reiman, Richard J. Caselli, Kewei Chen, Gene E. Alexander, Daniel Bandy, and Jennifer Frost Declining brain activity in cognitively normal apolipoprotein E 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease PNAS 2001 98: 3334-3339. [Abstract] [Full Text] [PDF]
    44. Ernst and Cohen Informed Consent in Complementary and Alternative Medicine Arch Intern Med 2001;161:2288-2292. FULL TEXT  
    45. Ernst, T., Chang, L., Jovicich, J., Ames, N., Arnold, S. (2002). Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 59: 1343-1349 [Abstract] [Full Text]  
    46. Evers, M. R., Salmen, B., Bukalo, O., Rollenhagen, A., Bosl, M. R., Morellini, F., Bartsch, U., Dityatev, A., Schachner, M. (2002). Impairment of L-type Ca2+ Channel-Dependent Forms of Hippocampal Synaptic Plasticity in Mice Deficient in the Extracellular Matrix Glycoprotein Tenascin-C. J. Neurosci. 22: 7177-7194 [Abstract] [Full Text]
    47. Fabiszewski KJ, Volicer B, Volicer L. Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients. JAMA. 1990;263:3168-3172. MEDLINE
    48. Fazel, S. (2002). Increased plasma total homocysteine levels increased the risk for dementia in the elderly. Evid Based Med 7: 160-160 [Full Text]  
    49. Foley, D. J., Masaki, K., White, L., Redline, S., Mignot, E., Murphy, Jr, G. M., Young, T. (2001). Relationship Between Apolipoprotein E {epsilon}4 and Sleep-Disordered Breathing at Different Ages. JAMA 286: 1447-1448 [Full Text]  
    50. Françoise Forette et al, The Prevention of Dementia With Antihypertensive Treatment,  New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study Arch Intern Med. 2002;162:2046-2052
    51. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B.Risk factors for late-onset Alzheimer's disease: a population-based, case-control study.Ann Neurol.1993;33:258-266.MEDLINE
    52. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging.1999;15:365-375. MEDLINE  
    53. Frenchman IB, Prince T. Clinical experience with risperidone, haliperidal and thioridazine for dementia-associated behavioural distubances. Int Psychogeriatr 9(4): 431-5 (Dec. 1997)  
    54. FRISONI, G B (2001). Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. J. Neurol. Neurosurg. Psychiatry 70: 711-718 [Full Text]  
    55. Fugh-Berman and Cott Dietary Supplements and Natural Products as Psychotherapeutic Agents Psychosom Med 1999;61:712-728. ABSTRACT | FULL TEXT  
    56. G. T. Grossberg and A. K. Desai Management of Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M331 - 353. [Full Text] [PDF]  
    57. Garibotto, G., Sofia, A., Saffioti, S., Russo, R., Deferrari, G., Rossi, D., Verzola, D., Gandolfo, M. T., Sala, M. R. (2003). Interorgan exchange of aminothiols in humans. Am. J. Physiol. 284: E757-763 [Abstract] [Full Text]  
    58. Gary W. Small, Linda M. Ercoli, Daniel H. S. Silverman, S.-C. Huang, Scott Komo, Susan Y. Bookheimer, Helen Lavretsky, Karen Miller, Prabha Siddarth, Natalie L. Rasgon, John C. Mazziotta, Sanjaya Saxena, H. M. Wu, Michael S. Mega, Jeffrey L. Cummings, Ann M. Saunders, Margaret A. Pericak-Vance, Allen D. Roses, Jorge R. Barrio, and Michael E. Phelps
      From the Cover: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
      PNAS 2000 97: 6037-6042; published online before print as 10.1073/pnas.090106797 [Abstract] [Full Text] [PDF]  
    59. Gayatri Devi, MD; Ruth Ottman, PhD; Ming-Xin Tang, PhD; Karen Marder, MD, MPH; Yaakov Stern, PhD; Richard Mayeux, MD, MSc Familial Aggregation of Alzheimer Disease Among Whites, African Americans, and Caribbean Hispanics in Northern Manhattan January 2000ABSTRACT     |   FULL TEXT     |   PDF
    60. Geerlings MI, Ruitenberg A, Witteman JCM, et al. Reproductive period and risk of dementia in postmenopausal women.
      JAMA. 2001;285:1475-1481.ABSTRACT  |  FULL TEXT  |  PDF
    61. George S. Alexopoulos, M.D. Jonathan M. Silver, M.D. David A. Kahn, M.D. Allen Frances, M.D. Daniel Carpenter, Ph.D The Expert Consensus Guideline Series, Treatment of Agitation in Older Persons with Dementia Editors for the Guidelines, .  www.psychguides.com/index.html  
    62. Goodman, A. B., Pardee, A. B. (2003). Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 100: 2901-2905 [Abstract] [Full Text]  
    63. Gossen, M., Bujard, H. (2002). STUDYING GENE FUNCTION IN EUKARYOTES BY CONDITIONAL GENE INACTIVATION. Annu. Rev. Genet. 36: 153-173 [Abstract] [Full Text]
    64. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    65. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1036. MEDLINE
    66. Greenberg, S. M. (2002). Cerebral amyloid angiopathy and dementia: Two amyloids are worse than one. Neurology 58: 1587-1588 [Full Text]  
    67. Greicius, M D, Geschwind, M D, Miller, B L (2002). Presenile dementia syndromes: an update on taxonomy and diagnosis. J. Neurol. Neurosurg. Psychiatry 72: 691-700 [Abstract] [Full Text]  
    68. Greicius, M D, Geschwind, M D, Miller, B L (2002). Presenile dementia syndromes: an update on taxonomy and diagnosis. J. Neurol. Neurosurg. Psychiatry 72: 691-700 [Abstract] [Full Text]  
    69. Grossberg and Desai Management of Alzheimer's Disease J Gerontol A Biol Sci Med Sci 2003;58:M331-353. FULL TEXT  
    70. Hachinski V.Vascular dementia: the need for a new approach. J Intern Med.1997;242:277-279.MEDLINE
    71. Han, Q., Xu, M., Tang, L., Tan, X., Tan, X., Tan, Y., Hoffman, R. M. (2002). Homogeneous, Nonradioactive, Enzymatic Assay for Plasma Pyridoxal 5-Phosphate. Clin Chem 48: 1560-1564 [Abstract] [Full Text]  
    72. Hariri, A. R, Weinberger, D. R (2003). Imaging genomics. Br Med Bull 65: 259-270 [Abstract] [Full Text]  
    73. Helene Benveniste, Gillian Einstein, Katie R. Kim, Christine Hulette, and G. Allan Johnson Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy
      PNAS 1999 96: 14079-14084.
      [Abstract] [Full Text] [PDF]
    74. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301. MEDLINE
    75. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM., Antibodies against beta-Amyloid Slow Cognitive Decline in Alzheimer's Disease. Neuron. 2003 May 22;38(4):547-54
    76. Homocysteine -- Risk Factor for Alzheimer's Disease?. Journal Watch Psychiatry 2002: 10-10 [Full Text]  
    77. Homocysteine -- Risk Factor for Alzheimer's Disease?. Journal Watch (General) 2002: 1-1 [Full Text]  
    78. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progesterone Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    79. Husaini, B. A., Moonis, M., Levine, R. (2003). Dementia and Hormone Use. PS 54: 575-575 [Full Text]  
    80. Iadecola, C., Gorelick, P. B. (2003). Converging Pathogenic Mechanisms in Vascular and Neurodegenerative Dementia. Stroke 34: 335-337 [Full Text]  
    81. J. F. Reilly, D. Games, R. E. Rydel, S. Freedman, D. Schenk, W. G. Young, J. H. Morrison, and F. E. Bloom Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model PNAS, April 15, 2003; 100(8): 4837 - 4842.  [Abstract] [Full Text] [PDF]  
    82. Jack, C. R. , Petersen, R. C. , Xu, Y. , O'Brien, P. C. , Smith, G. E. , Ivnik, R. J. , Boeve, B. F. , Tangalos, E. G. & Kokmen, E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD (2000) Neurology 55, 484-489
    83. Jakubowski, H. (2002). Homocysteine Is a Protein Amino Acid in Humans. IMPLICATIONS FOR HOMOCYSTEINE-LINKED DISEASE. J. Biol. Chem. 277: 30425-30428 [Abstract] [Full Text]  
    84. K. Scott, R. M. Lawrence, A. Duggal, C. Darwin, E. Brooks, and G. Christodoulou Prescribing patterns for psychotic and behavioural symptoms in dementia: a national survey Psychiatr. Bull., August 1, 2002; 26(8): 288 - 290.  [Abstract] [Full Text] [PDF]  
    85. Kapur, N., Kopelman, M. D (2003). Advanced brain imaging procedures and human memory disorder. Br Med Bull 65: 61-81 [Abstract] [Full Text]  
    86. Kato, T., Knopman, D., Liu, H. (2001). Dissociation of regional activation in mild AD during visual encoding: A functional MRI study. Neurology 57: 812-816 [Abstract] [Full Text]  
    87. Kawas C, Resnick S, Morrison A, et al.A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging.Neurology.1997;48:1517-1521.MEDLINE 
    88. Kelly, C. A. , Harvey, R. J. & Cayton, H. (1997)Drug treatments for Alzheimer's disease Br. Med. J. 314, 693-694
    89. Knable Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia Evid Based Ment Health 2002;5:90-90.
      FULL TEXT  
    90. Korczyn, A. D. (2002). Homocysteine, Stroke, and Dementia. Stroke 33: 2343-2344 [Full Text]  
    91. Krause, B. J. , Schmidt, D. , Mottaghy, F. M. , Taylor, J. , Halsband, U. , Herzog, H. , Tellmann, L. & Muller-Gartner, H. W. Episodic retrieval activates the precuneus irrespective of the imagery content of word pair associates A PET study  (2001) Brain 122, 255-263
    92. Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., Bernabei, R. (2003). Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients. AJGP 11: 179-185 [Abstract] [Full Text]  
    93. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA.2001;285:1489-1499. ABSTRACT  |  FULL TEXT  |  PDF 
    94. Leveille SG, LaCroix AZ, Newton KM, Keenan NL. Older women and hormone replacement therapy: factors influencing late life initiation. J Am Geriatr Soc. 1997;45:1496-1500. MEDLINE
    95. Levine, B, Cabeza, R, McIntosh, A R, Black, S E, Grady, C L, Stuss, D T (2002). Functional reorganisation of memory after traumatic brain injury: a study with H2150 positron emission tomography. J. Neurol. Neurosurg. Psychiatry 73: 173-181 [Abstract] [Full Text]  
    96. Levine, J., Stahl, Z., Sela, B. A., Gavendo, S., Ruderman, V., Belmaker, R. H. (2002). Elevated Homocysteine Levels in Young Male Patients With Schizophrenia. Am. J. Psychiatry 159: 1790-1792 [Abstract] [Full Text]  
    97. Li, S.-J., Li, Z., Wu, G., Zhang, M.-J., Franczak, M., Antuono, P. G. (2002). Alzheimer Disease: Evaluation of a Functional MR Imaging Index as a Marker. Radiology 225: 253-259 [Abstract] [Full Text]  
    98. Loeb C, Gandolfo C.Diagnostic evaluation of degenerative and vascular dementia.Stroke. 1983;14:399-401.MEDLINE
    99. Lokk, J. (2003). News and Views on Folate and Elderly Persons. J Gerontol A Biol Sci Med Sci 58: M354-361 [Abstract] [Full Text]  
    100. Lovestone, S (2002). Can we afford to develop treatments for dementia?. J. Neurol. Neurosurg. Psychiatry 72: 685-685 [Full Text]  
    101. Luchsinger, J. A., Tang, M.-X., Shea, S., Mayeux, R. (2003). Antioxidant Vitamin Intake and Risk of Alzheimer Disease. Arch Neurol 60: 203-208 [Abstract] [Full Text]  
    102. M. J. de Leon, A. Convit, O. T. Wolf, C. Y. Tarshish, S. DeSanti, H. Rusinek, W. Tsui, E. Kandil, A. J. Scherer, A. Roche, A. Imossi, E. Thorn, M. Bobinski, C. Caraos, P. Lesbre, D. Schlyer, J. Poirier, B. Reisberg, and J. Fowler Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET) PNAS 2001 98: 10966-10971; published online before print as 10.1073/pnas.191044198 [Abstract] [Full Text] [PDF]
    103. M. Lepage, O. Ghaffar, L. Nyberg, and E. Tulving From the Cover: Prefrontal cortex and episodic memory retrieval mode PNAS, January 4, 2000; 97(1): 506 - 511. [Abstract] [Full Text] [PDF]
    104. M.J. DeLeon, T. Crook:The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry, 139, 1136-1139 (1982).)
    105. Madeline Murguia Rice, PhD; Amy Borenstein Graves, PhD; Susan M. McCurry, PhD; Laura E. Gibbons, PhD; Jim D. Bowen, MD; Wayne C. McCormick, MD; Eric B. Larson, MD, MPH Arch Intern Med. 2000;160:1641-1649
    106. Maidment The use of ginkgo biloba in the treatment of dementia Psychiatr Bull 2001;25:353-356. ABSTRACT | FULL TEXT  
    107. Marquis, S., Moore, M. M., Howieson, D. B., Sexton, G., Payami, H., Kaye, J. A., Camicioli, R. (2002). Independent Predictors of Cognitive Decline in Healthy Elderly Persons. Arch Neurol 59: 601-606 [Abstract] [Full Text]  
    108. Mattson, M. P. (2003). Will caloric restriction and folate protect against AD and PD?. Neurology 60: 690-695 [Abstract] [Full Text]  
    109. Mattson, M. P., Duan, W., Guo, Z. (2003). Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J Neurochem 84: 417-431 [Abstract] [Full Text]  
    110. Mayeux and Sano Treatment of Alzheimer's Disease N Engl J Med 1999;341:1670-1679. FULL TEXT  
    111. Mayeux, R., Small, S. A. (2000). Finding the Beginning or Predicting the Future?. Arch Neurol 57: 783-784 [Full Text]  
    112. Mazurek, A. A., De Deyn, P. P., Mayeux, R., Sano, M. (2000). Treatment of Alzheimer's Disease. N Engl J Med 342: 821-822 [Full Text]  
    113. Mega, M. S., Small, G. W., Xu, M. L., Felix, J., Manese, M., Tran, N. P., Dailey, J. I., Ercoli, L. M., Bookheimer, S. Y., Toga, A. W. (2002). Hippocampal Atrophy in Persons With Age-Associated Memory Impairment: Volumetry Within a Common Space. Psychosom Med 64: 487-492 [Abstract] [Full Text]  
    114. Merrill F. Elias, PhD, MPH; Alexa Beiser, PhD;   Philip A. Wolf, MD; Rhoda Au, PhD;   Roberta F. White, PhD; Ralph B. D'Agostino, PhD The Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort   http://archneur.ama-assn.org/issues/v57n6/abs/noc90027.html Arch Neurol. 2000;57:808-813
    115. Miller, B. L. (2002). Past Glory and Future Promise: Maximizing and Improving Understanding of Atrophy Patterns in the Diagnosis of Degenerative Dementias. AJNR Am J Neuroradiol 23: 33-34 [Full Text]  
    116. Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., Wolf, P. A. (2003). Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status. Neurology 60: 1125-1129 [Abstract] [Full Text]  
    117. Montine, T. J., Milatovic, D., Gupta, R. C., Valyi-Nagy, T., Morrow, J. D., Breyer, R. M. (2002). Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 83: 463-470 [Abstract] [Full Text]  
    118. Morley, J. E. (2003). Editorial: Hot Topics in Geriatrics. J Gerontol A Biol Sci Med Sci 58: M30-36 [Full Text]  
    119. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Wilson, R. S. (2002). Vitamin E and Cognitive Decline in Older Persons. Arch Neurol 59: 1125-1132 [Abstract] [Full Text]  
    120. Morrison RS, Siu AL. Mortality from pneumonia and hip fractures in patients with advanced dementia [letter]. JAMA. 2000;284:2447-2448. FULL TEXT  |  PDF  |  MEDLINE
    121. Morrison RS, Siu AL. Survival in end-stage dementia following acute illness. JAMA. 2000;284:47-52. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    122. MRI Aids in Diagnosis of Early Alzheimer's Disease. Journal Watch Psychiatry 2000: 5-5 [Full Text]  
    123. Mueggler, T., Sturchler-Pierrat, C., Baumann, D., Rausch, M., Staufenbiel, M., Rudin, M. (2002). Compromised Hemodynamic Response in Amyloid Precursor Protein Transgenic Mice. J. Neurosci. 22: 7218-7224 [Abstract] [Full Text]  
    124. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA. 2000;283:1007-1015 ABSTRACT  |  FULL TEXT  
    125. Nahin and Straus Research into complementary and alternative medicine: problems and potential BMJ 2001;322:161-164. FULL TEXT  
    126. Neugroschl, J., Davis, K. L. (2002). Biological Markers in Alzheimer Disease. AJGP 10: 660-677 [Abstract] [Full Text]  
    127. New Treatments for Alzheimer's Disease Reviewed. Journal Watch Neurology 2000: 3-3 [Full Text]  
    128. Nobili, F., Koulibaly, M., Vitali, P., Migneco, O., Mariani, G., Ebmeier, K., Pupi, A., Robert, P. H., Rodriguez, G., Darcourt, J. (2002). Brain Perfusion Follow-Up in Alzheimer's Patients During Treatment with Acetylcholinesterase Inhibitors. J Nucl Med 43: 983-990 [Abstract] [Full Text]  
    129. NSAID Use and Risk for Alzheimer's Disease. Journal Watch (General) 2001: 2-2 [Full Text]  
    130.  NSAID Use and Risk for Alzheimer's Disease. Journal Watch Psychiatry 2002: 9-9 [Full Text]  
    131. O. L. Lopez, S. R. Wisniewski, J. T. Becker, F. Boller, and S. T. DeKosky Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease Arch Neurol, October 1, 1999; 56(10): 1266 - 1272.  [Abstract] [Full Text] [PDF]  
    132. O'Hara et al. Update on Alzheimer's disease: recent findings and treatments eWJM 2000;172:115-120.FULL TEXT  
    133. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch Neurol 1998;55:1409-1415
    134. Paganini-Hill A, Henderson VW.Estrogen deficiency and risk of Alzheimer's disease in women.Am J Epidemiol.1994;140:256-261.MEDLINE
    135. Paganini-Hill A, Henderson VW.Estrogen replacement therapy and risk of Alzheimer disease.Arch Intern Med.1996;156:2213-2217.MEDLINE
    136. Pantano, P., Iannetti, G. D., Caramia, F., Mainero, C., Di Legge, S., Bozzao, L., Pozzilli, C., Lenzi, G. L. (2002). Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain 125: 1607-1615 [Abstract] [Full Text]  
    137. Pedreira, M. E., Perez-Cuesta, L. M., Maldonado, H. (2002). Reactivation and Reconsolidation of Long-Term Memory in the Crab Chasmagnathus: Protein Synthesis Requirement and Mediation by NMDA-Type Glutamatergic Receptors. J. Neurosci. 22: 8305-8311 [Abstract] [Full Text]
    138. Peskind, E. R., Wilkinson, C. W., Petrie, E. C., Schellenberg, G. D., Raskind, M. A. (2001). Increased CSF cortisol in AD is a function of APOE genotype. Neurology 56: 1094-1098 [Abstract] [Full Text]  
    139. Petitti DB, Buckwalter JG, Crooks VC, Chiu V. Prevelence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol A Biol Sci Med Sci. 2002;57:M532-M538. MEDLINE
    140. Petrella, J. R., Coleman, R. E., Doraiswamy, P. M. (2003). Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future. Radiology 226: 315-336 [Abstract] [Full Text]  
    141. Petrella, J. R., Lustig, C., Bucher, L. A., Jha, A. P., Doraiswamy, P. M. (2002). Prefrontal Activation Patterns in Subjects at Risk for Alzheimer Disease. AJGP 10: 112-113 [Full Text]  
    142. Pope, S. K., Shue, V. M., Beck, C. (2003). WILL A HEALTHY LIFESTYLE HELP PREVENT ALZHEIMER'S DISEASE?. Annu. Rev. Public Health 24: 111-132 [Abstract] [Full Text]  
    143. Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., Morris, J. C. (2001). Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Arch Neurol 58: 1395-1402 [Abstract] [Full Text]  
    144. Prins, N.D., den Heijer, T., Hofman, A., Koudstaal, P.J., Jolles, J., Clarke, R., Breteler, M.M.B. (2002). Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 59: 1375-1380 [Abstract] [Full Text]  
    145. R. I. Scahill, J. M. Schott, J. M. Stevens, M. N. Rossor, and N. C. Fox Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI PNAS, April 2, 2002; 99(7): 4703 - 4707. [Abstract] [Full Text] [PDF]
    146. Rachael I. Scahill, Jonathan M. Schott, John M. Stevens, Martin N. Rossor, and Nick C. Fox Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI PNAS 2002 99: 4703-4707. [Abstract] [Full Text] [PDF]  
    147. Rampersaud, G. C., Kauwell, G. P.A., Bailey, L. B. (2003). Folate: A Key to Optimizing Health and Reducing Disease Risk in the Elderly. J Am Coll Nutr 22: 1-8 [Abstract] [Full Text]  
    148. Ravaglia, G., Forti, P., Maioli, F., Muscari, A., Sacchetti, L., Arnone, G., Nativio, V., Talerico, T., Mariani, E. (2003). Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am. J. Clin. Nutr. 77: 668-673 [Abstract] [Full Text]  
    149. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., Mobius, H. J., the Memantine Study Group, (2003). Memantine in Moderate-to-Severe Alzheimer's Disease. N Engl J Med 348: 1333-1341 [Abstract] [Full Text]
    150. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002;288:2170-2172. FULL TEXT  |  PDF  |  MEDLINE
    151. Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive and brain aging. Ann N Y Acad Sci. 2001;949:203-214. MEDLINE
    152. Reynolds, E H (2002). Folic acid, ageing, depression, and dementia. BMJ 324: 1512-1515 [Full Text]  
    153. Rigaud AS, Seux ML, Staessen JA, Birkenhäger WH, Forette F.Cerebral complications of hypertension.
      J Hum Hypertens.2000;14:605-616.MEDLINE
    154. Riva E, Nobili A, Tecate F. "Judicious" use of neuroleptic drugs in the treatment of behavioral symptoms in the course of Alzheimer Disease. Recenti Prg Med 89(11): 598-603 (Nov. 1998)
    155. Rogers, J. D., Sanchez-Saffon, A., Frol, A. B., Diaz-Arrastia, R. (2003). Elevated Plasma Homocysteine Levels in Patients Treated With Levodopa: Association With Vascular Disease. Arch Neurol 60: 59-64 [Abstract] [Full Text]  
    156. RUCHOUX, M.-M., BRULIN, P., BRILLAULT, J., DEHOUCK, M.-P., CECCHELLI, R., BATAILLARD, M. (2002). Lessons from CADASIL. Annals NYAS Online 977: 224-231 [Abstract] [Full Text]  
    157. S. S. Sisodia and M. Gallagher A role for the beta -amyloid precursor protein in memory? PNAS, October 13, 1998; 95(21): 12074 - 12076. [Full Text] [PDF
    158. Santini, E., Muller, R. U., Quirk, G. J. (2001). Consolidation of Extinction Learning Involves Transfer from NMDA-Independent to NMDA-Dependent Memory. J. Neurosci. 21: 9009-9017 [Abstract] [Full Text]
    159. Selkoe, D. J. (2002). Alzheimer's Disease Is a Synaptic Failure. Science 298: 789-791 [Abstract] [Full Text]  
    160. Selkoe, D. J., Schenk, D. (2003). ALZHEIMER'S DISEASE: Molecular Understanding Predicts Amyloid-Based Therapeutics. Annu. Rev. Pharmacol. Toxicol. 43: 545-584 [Abstract] [Full Text]  
    161. Shea, T. B., Rogers, E., Auer, J., Berent, R., Eber, B., Seshadri, S., Wolf, P. A. (2002). Homocysteine and Dementia. N Engl J Med 346: 2007-2008 [Full Text]  
    162. Sheehan, B., Fazel, S. (2002). Elevated plasma total homocysteine increased the risk of dementia in the elderly. Evid Based Ment Health 5: 126-126 [Full Text]  
    163. Shi, Q., Savage, J. E., Hufeisen, S. J., Rauser, L., Grajkowska, E., Ernsberger, P., Wroblewski, J. T., Nadeau, J. H., Roth, B. L. (2003). L-Homocysteine Sulfinic Acid and Other Acidic Homocysteine Derivatives Are Potent and Selective Metabotropic Glutamate Receptor Agonists. J. Pharmacol. Exp. Ther. 305: 131-142 [Abstract] [Full Text]  
    164. Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76:906-909. MEDLINE
    165. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19:604-621. MEDLINE
    166. Silverman, D. H.S., Small, G. W. (2002). Prompt Identification of Alzheimer's Disease With Brain PET Imaging of a Woman With Multiple Previous Diagnoses of Other Neuropsychiatric Conditions. Am. J. Psychiatry 159: 1482-1488 [Full Text]  
    167. Simona Capsoni, Gabriele Ugolini, Alessandro Comparini, Francesca Ruberti, Nicoletta Berardi, and Antonino Cattaneo Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice PNAS 2000 97: 6826-6831. [Abstract] [Full Text] [PDF]
    168. Skoog, I. (2000). Detection of Preclinical Alzheimer's Disease. N Engl J Med 343: 502-503 [Full Text]  
    169. Sloane et al. THE PUBLIC HEALTH IMPACT OF ALZHEIMER'S DISEASE, 2000-2050: Potential Implication of Treatment Advances Annu. Rev. Public Health 2002;23:213-231. ABSTRACT | FULL TEXT  
    170. Smith, A D. (2002). Homocysteine, B vitamins, and cognitive deficit in the elderly. Am. J. Clin. Nutr. 75: 785-786 [Full Text]  
    171. Smith, A. D. (2002). Imaging the progression of Alzheimer pathology through the brain. Proc. Natl. Acad. Sci. U. S. A. 99: 4135-4137 [Full Text]  
    172. Smith, C. D., Andersen, A. H., Kryscio, R. J., Schmitt, F. A., Kindy, M. S., Blonder, L. X., Avison, M. J. (2002). Women at risk for AD show increased parietal activation during a fluency task. Neurology 58: 1197-1202 [Abstract] [Full Text]  
    173. Sood, A., Mounier, N., Andre, M., Lepage, E., Hull, M., Lieb, K., Fiebich, B. L., Press, D., Stricker, B. H.C., Hofman, A., Breteler, M. M.B. (2002). Nonsteroidal Drugs and Alzheimer's Disease. N Engl J Med 346: 1171-1173 [Full Text]  
    174. Sperling, R A, Bates, J F, Chua, E F, Cocchiarella, A J, Rentz, D M, Rosen, B R, Schacter, D L, Albert, M S (2003). fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74: 44-50 [Abstract] [Full Text]  
    175. Stein, T. D., Johnson, J. A. (2002). Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways. J. Neurosci. 22: 7380-7388 [Abstract] [Full Text]  
    176. Sudha Seshadri, MD; Gwen L. Zornberg, MD, ScD;  Laura E. Derby, DSc; Marian W. Myers, MPH; Hershel Jick, MD; David A. Drachman, MD Postmenopausal Estrogen Replacement Therapy and the Risk of Alzheimer Disease Arch Neurol. 2001;58:435-44
    177. T. A. Rummans, E. C. Lauterbach, C. E. Coffey, D. R. Royall, J. L. Cummings, S. Salloway, J. Duffy, and D. Kaufer Pharmacologic Efficacy in Neuropsychiatry: A Review of Placebo-Controlled Treatment Trials J. Neuropsychiatry. Clin. Neurosci., May 1, 1999; 11(2): 176 - 189.  [Abstract] [Full Text]  
    178. T. Greenhalgh, K. Stein, R. Milne, L. Best, H Boothby, S M N Zaidi, V Seth, S Khalaf, H Jameel, S Mahomed, A. Yassiri, P Hooper, A M Whitehead, R. W Jones, J. B Mann, and S. A Saunders Advertisements for donepezil BMJ, December 13, 1997; 315(7122): 1623 - 1623. [Full Text]
    179. Tang MX, Jacobs D, Stern Y, et al.Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.Lancet.1996;348:429-432.MEDLINE
      Tariot PN, Erb R, Podgorski CA, et al.
      Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61
    180. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada.Neurology.1994;44:2073-2080.MEDLINE
    181. Toole, J. F., Jack, C. R. (2002). Food (and vitamins) for thought. Neurology 58: 1449-1450 [Full Text]  
    182. Trojanowski, J. Q. (2002). Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease : Key to Elucidating Neurodegenerative Pathways and Identifying New Targets for Drug Discovery. Am J Pathol 160: 409-411 [Full Text]  
    183. Trojanowski, J. Q. (2002). Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease : Key to Elucidating Neurodegenerative Pathways and Identifying New Targets for Drug Discovery. Am J Pathol 160: 409-411 [Full Text]  
    184. van der Steen JT, Ooms ME, Adèr HJ, Ribbe MW, van der Wal G. Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. Arch Intern Med. 2002;162:1753-1760. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    185. van der Steen JT, Ooms ME, van der Wal G, Ribbe MW. Pneumonia: the demented patient's best friend? discomfort after starting or withholding antibiotic treatment. J Am Geriatr Soc. 2002;50:1681-1688. MEDLINE
    186. Van Duijn CM, Clayton D, Chandra V, et al.Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies.Int J Epidemiol.1991;20(suppl 2):S13-S19.MEDLINE
    187. van Leeuwen, R, Vingerling, J R, Hofman, A, de Jong, P T V M, Stricker, B H C. (2003). Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 326: 255-256 [Full Text]  
    188. Varner, A. E., Brenner, S., Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N., Wilson, R. S., Scherr, P. A., Engelhart, M. J., Breteler, M. M. B. (2002). Antioxidants and Risk of Alzheimer Disease. JAMA 288: 2265-2266 [Full Text]  
    189. Venn, B. J., Grant, A. M., Thomson, C. D., Green, T. J. (2003). Selenium Supplements Do Not Increase Plasma Total Homocysteine Concentrations in Men and Women. J. Nutr. 133: 418-420 [Abstract] [Full Text]  
    190. WAKUTANI, Y., KOWA, H., KUSUMI, M., YAMAGATA, K., WADA-ISOE, K., ADACHI, Y., TAKESHIMA, T., URAKAMI, K., NAKASHIMA, K. (2002). Genetic Analysis of Vascular Factors in Alzheimer's Disease. Annals NYAS Online 977: 232-238 [Abstract] [Full Text]  
    191.  Wancata, Johannes ,Psychiat. Prax. 2000; 27: Nr. 4, S. 171-176.   Wien.
    192. Wang, H., Shimizu, E., Tang, Y.-P., Cho, M., Kyin, M., Zuo, W., Robinson, D. A., Alaimo, P. J., Zhang, C., Morimoto, H., Zhuo, M., Feng, R., Shokat, K. M., Tsien, J. Z. (2003). Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc. Natl. Acad. Sci. U. S. A. 100: 4287-4292 [Abstract] [Full Text]
    193. Wargovich et al. Herbals, Cancer Prevention and Health J. Nutr. 2001;131:3034S-3036. ABSTRACT | FULL TEXT  
    194. Watson, W. H., Cai, J., Jones, D. P. (2000). DIET AND APOPTOSIS. Annu. Rev. Nutr. 20: 485-505 [Abstract] [Full Text]  
    195. Wells, D. G., Dong, X., Quinlan, E. M., Huang, Y.-S., Bear, M. F., Richter, J. D., Fallon, J. R. (2001). A Role for the Cytoplasmic Polyadenylation Element in NMDA Receptor-Regulated mRNA Translation in Neurons. J. Neurosci. 21: 9541-9548 [Abstract] [Full Text]
    196. WHALLEY, L. J. (2002). Brain ageing and dementia: what makes the difference?. Br J Psychiatry 181: 369-371 [Full Text]  
    197. Whitmer, R. A., Haan, M. N., Miller, J. W., Yaffe, K. (2003). Hormone Replacement Therapy and Cognitive Performance: The Role of Homocysteine. J Gerontol A Biol Sci Med Sci 58: M324-330 [Abstract] [Full Text]  
    198. Writing Group for the Women Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    199. Xu, J., Chen, S., Ahmed, S. H., Chen, H., Ku, G., Goldberg, M. P., Hsu, C. Y. (2001). Amyloid-{beta} Peptides Are Cytotoxic to Oligodendrocytes. J. Neurosci. 21: 118R-118 [Abstract] [Full Text]  
    200. Xu, Y. , Jack, C. R., Jr. , O'Brien, P. C. , Kokmen, E. , Smith, G. E. , Ivnik, R. J. , Boeve, B. F. , Tangalos, R. G. & Petersen, R. C. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD (2000) Neurology 54, 1760-1767
    201. Yen, C.-H., Lau, Y.-T. (2002). Vascular Responses in Male and Female Hypertensive Rats With Hyperhomocysteinemia. Hypertension 40: 322-328 [Abstract] [Full Text]  
    202. Zandi PP, Carlson MC, Plassman BL, et al, for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288:2123-2129. ABSTRACT  |  FULL TEXT  |  PDF  |  MEDLINE
    203. Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., Breitner, J. C.S. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 59: 880-886 [Abstract] [Full Text]  
    204. Zandi, P. P., Carlson, M. C., Plassman, B. L., Welsh-Bohmer, K. A., Mayer, L. S., Steffens, D. C., Breitner, J. C. S., for the Cache County Memory Study Investigators, (2002). Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women: The Cache County Study. JAMA 288: 2123-2129 [Abstract] [Full Text]  
    205. Maria-Jesús Sobrido, MD, et al, Novel Tau Polymorphisms, Tau Haplotypes, and Splicing in Familial and Sporadic Frontotemporal Dementia, Arch Neurol. 2003;60:698-702.
    206. Lawrence S. Honig, et al., Atherosclerosis and AD; Analysis of data from the US National Alzheimer’s Coordinating Center NEUROLOGY 2005;64:494-500'
    207. R. A. Whitmer, Midlife cardiovascular risk factors and risk of dementia in late life NEUROLOGY 2005;64:277-281

Links  aktuelles


Artikel der Ärztezeitung zu Alzheimer    Demenz

Deutsches Zentrum für Altersfragen e.V.
The Merck Manual of Geriatrics


Demenz Ratgeber der TK

Viele Infos bei www.alzheimerforum.de Deutsche Alzheimer Gesellschaft e. V. Bundesverband von Alzheimer Landesverbänden sowie von regionalen und örtlichen Gesellschaften. Allgemeiner Demenz-Ratgeber Ist ein Informations-Service für Betreuer Demenz-Kranker. Alzheimer Online Informationssystem
Informationen für Interessierte, Betroffene, Angehörige, Ärzte, Apotheker und Fachkreise
Alzheimer-Ethik Informationen und Anregungen zum Umgang mit dementen Menschen. Alzheimer-Krankheit - Gesundheitsserver Knoll GmbH Demenz-Spektrum Informationen über die Alzheimer Krankheit aus der WDR-Sendung Quarks & Co.

www.zdf.de/ratgeber/praxis/archiv, www.schoen-kliniken.de   www.vetera.de/info009.htm                                                             www.martin-ruppenthal.de/medi.htm www.alois.de   www.neurogeriatrie.de

Pfizer (Alzheimer Expertensystem) Alzheimers's and Neurodegenerative Diseases Alzheimer Research Group (Universität Düsseldorf Web Resources Alzheimer's Association MGH Lab of Genetics and Aging: MGH Web Forum: Alzheimer's Disease DEAR: Alzheimer's Disease Educ. & Referral Center Alzheimer's Disease Resource Page Alzheimer Research Forum Alzheimers.Com Alzheimer's Web  Alzheimer's Association  Dementia Neuropathology/Tissue Research   Diagnosing Alzheimer's Disease Alzheimer's Disease: A Primary Care Approach Dementia With Lewy Bodies - A Distinct Non-Alzheimer Syndrome?  Lewy-Net PET Scan of an Alzheimer Patient    Use of Apolipoprotein E Testing for AD Advances in the Treatment of Alzheimer's Disease Anti-Inflammatory Drugs May Help Reduce Risk Of Alzheimer's Disease The efficacy of tacrine ... Donepezil Approved for Alzheimers Disease Chromosome 21 Consortium Genetic Alzheimer's Clues Alzheimer's Association Australia Nancze's Alzheimer's Awareness and CareGiver's Haven Alzheimer’s Disease, MRI of Hippocampus In Incipient Kriterienkatalog Alzheimer's Disease (AZ) Subfile of CHID Online NIMH Alzheimer's Disease Genetics Dataset

Alzheimer Web Home Page Alzheimer's Association Alzheimer's Disease - Doctor's Guide to the Internet Alzheimers Disease Patient Forum Dementia of the Alzheimer Type European Alzheimer Clearing House (EACH) Healthtouch - Diagnosing Alzheimer's Disease  INND - Alzheimer's Disease Surfbrett

Zurück zur Startseite Demenz


Zur Startseite Anschrift des Verfassers: (Praxisadresse)
Feedback: Karl C. Mayer
Gästebuch Bergheimerstraße 56a
E-Mail 69115 Heidelberg
Bitte beachten Sie, diese Webseite ersetzt keine medizinische Diagnosestellung oder Behandlung. Es wird hier versucht einen Überblick über den derzeitigen Stand der medizinischen Forschung auch für interessierte Laien  zu geben, dies ist nicht immer aktuell möglich. Es ist auch nicht möglich, dass ein Arzt immer auf dem aktuellsten Stand der medizinischen Forschung in allen Bereichen seines Faches ist.  Es ist immer möglich, dass die medizinische Forschung hier noch als wirksam und ungefährlich dargestellte Behandlungsmaßnahmen inzwischen als gefährlich oder unwirksam erwiesen hat. Lesen Sie bei Medikamenten immer den Beipackzettel und fragen Sie bei Unklarheiten Ihren behandelnden Arzt. Medikamentöse Behandlungen auch mit freiverkäuflichen Medikamenten bedürfen ärztlicher Aufsicht und Anleitung. Dies gilt auch für alle anderen Behandlungsverfahren. Die hier angebotenen Informationen können nicht immer für jeden verständlich sein. Um Mitteilung wo dies nicht der Fall ist bin ich dankbar. Fragen Sie hierzu immer Ihren behandelnden Arzt. Dieser weiß in der Regel über die hier dargestellten Sachverhalte gut Bescheid und kann Ihren individuellen Fall und Ihre Beschwerden besser einordnen- was für einen bestimmten Patienten nützlich ist, kann einem anderen schaden.  Selbstverständlich gibt es zu den meisten Themen unterschiedliche Auffassungen. Soweit möglich wird hier dargestellt woher die Informationen stammen. In den meisten Fällen mit einem entsprechenden Link (da diese oft ohne Ankündigung geändert werden, sind diese leider nicht immer aktuell zu halten).. Leider ist die zitierte Literatur nicht immer kostenfrei zugänglich. Die Beschränkung auf kostenfrei zugängliche Literatur würde manches sehr oberflächlich lassen. In der Regel versuche ich mich in der Darstellung an deutschen oder internationalen Leitlinien der Fachgesellschaften und Metaanalysen der Literatur zu orientieren. Auch dies ist nicht überall möglich. Zum einen gibt es nicht überall solche Leitlinien, zum anderen werden diese mir nicht immer sofort bekannt. Manche Leitlinien sind lange nicht aktualisiert worden und von neuerer Literatur überholt, bzw, ergänzungsbedürftig.  Wenn möglich sind im Text Links zu solchen Leitlinien eingebaut. Auch Leitlinien sind nur Orientierungen, sie schließen nicht aus, dass generell oder im Einzelfall Fehler enthalten sind oder diese im Einzelfall nicht anwendbar sind. Ziel der Darstellung ist hier definitiv nicht, mich als Experten für irgendeines der in der Homepage dargestellten Krankheitsbilder auszuweisen. Ich gehe davon aus, dass alle vergleichbaren Fachärzte für Neurologie, Psychotherapeutische Medizin und Psychiatrie ihre Patienten sorgfältig und genau so gut wie ich behandeln. Sollten Sie über eine Suchmaschine direkt auf diese Seite gekommen sein, werden Sie gebeten auch die Hauptseite aufzusuchen. Dort finden Sie einen Link zu den zuständigen Ärztekammern. Bitte lesen sie auch den Beipackzettel der Homepage und das Vorwort. Jeder Nutzer ist für die Verwendung der hier gewonnenen Informationen selbst verantwortlich, es handelt sich definitiv um keine Anleitung zur Selbstbehandlung. Es wird keinerlei Haftung weder für die hier angebotenen Informationen noch für die in den Links angebotenen Informationen übernommen. Sollten Sie Links finden, die nicht (oder nicht mehr) seriös sind, teilen Sie mir dies bitte mit, damit ich diese löschen kann. Der Autor übernimmt keinerlei Gewähr für die Aktualität, Korrektheit, Vollständigkeit oder Qualität der bereitgestellten Informationen. Haftungsansprüche gegen den Autor, welche sich auf Schäden materieller oder ideeller Art beziehen, die durch die Nutzung oder Nichtnutzung der dargebotenen Informationen bzw. durch die Nutzung fehlerhafter und unvollständiger Informationen verursacht wurden sind grundsätzlich ausgeschlossen, sofern seitens des Autors kein nachweislich vorsätzliches oder grob fahrlässiges Verschulden vorliegt. Alle Angebote sind freibleibend und unverbindlich. Der Autor behält es sich ausdrücklich vor, Teile der Seiten oder das gesamte Angebot ohne gesonderte Ankündigung zu verändern, zu ergänzen, zu löschen oder die Veröffentlichung zeitweise oder endgültig einzustellen. Veränderungen erfolgen dabei ständig in Anpassung an neue Literatur oder weil sich meine Auffassung zu einem Thema aus anderen Gründen geändert hat.  Dieser Haftungsausschluss ist als Teil des Internetangebotes zu betrachten, von dem aus auf diese Seite verwiesen wurde. Sofern Teile oder einzelne Formulierungen dieses Textes der geltenden Rechtslage nicht, nicht mehr oder nicht vollständig entsprechen sollten, bleiben die übrigen Teile des Dokumentes in ihrem Inhalt und ihrer Gültigkeit davon unberührt.  Sollte sich jemand durch die Homepage in irgendeiner Form beleidigt, benachteiligt oder in sonst einer Form geschädigt fühlen, bitte ich um eine persönliche Kontaktaufnahme per E-mail   oder telefonisch bzw. per Post. Bitte nennen Sie bei Mitteilungen Ihren vollständigen Namen und Ihre Adresse. Bei Mitteilungen von Kollegen bitte auch Tatsache, dass sie Kollege sind, sowie die Fachbezeichnung. Anonyme Mitteilungen sind in der Regel nicht willkommen. Karl C. Mayer